Head-to-head · WeighScore
Renlo Health vs Vitalex Health
By GLP-1 ScorecardUpdated
Score comparison
Renlo Health has the higher recorded score — 79.7/100 to 59.7/100.
Renlo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs whose headline is the actual monthly rate, with the prescribing physician and the dispensing pharmacy both named.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Renlo Health | Vitalex Health |
|---|---|---|
| WeighScore | 79.7/100 | 59.7/100 |
| Grade | C+ | C |
| Site position | #41 | #384 |
| Semaglutide | $199/mo, billed monthly at every dose | $199/mo (starting dose, compounded) |
| Tirzepatide | $269/mo, billed monthly at every dose | $199/mo (starting dose, compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #41 · C+
Strengths
- The headline is the real month-to-month rate — no prepay division and no commitment behind an asterisk
- A genuine all-in line: medication, injection supplies, provider evaluation, ongoing care, expedited shipping and unlimited care-team messaging, with no membership or consultation fees
- Names the prescribing physician, Dr. Sean Arora, MD, and the dispensing pharmacy, VialsRX
- Same price at every dose with a price-lock badge
- A four-month money-back guarantee, and cancel anytime with no fee
What to consider
- A struck-through $399 sits beside the price with no published basis — Renlo never says what it was, when it applied or to whom
- That strikethrough comes from a stylesheet rule rather than a struck-out element, so a markup-level check would report the page clean
- A comparison table headed "Most GLP-1 providers" quotes $270, $365 and $445 by dose while naming no provider and citing no source
- A site-wide $50 code means the advertised figure is not the first amount charged
- No lab protocol is published, and there is no oral or brand route
Site position #384 · C
Strengths
- Flat-rate pricing starting at $199/mo with no consultation fee or dose-change surcharges
- Three distinct programs — Semaglutide, Tirzepatide, and a lower-dose GLP-1 Microdose protocol for body composition
- Names its legal entity (Vitalex Health, LLC), a real street address, phone number, and posted clinical hours
- Named lead clinician (Laqueta Nelson, MSN, FNP-BC) instead of an anonymous care team
- Working Terms of Service, Privacy Policy, and HIPAA Notice pages, not dead links
What to consider
- Brands itself “physician-led” sitewide, but the only named clinician is a nurse practitioner (FNP-BC), not a physician
- No LegitScript seal or other third-party pharmacy-verification badge found anywhere on the site
- Compounding pharmacy and prescribing medical group are referenced only generically — neither is named
- Exact price is not published — the $199/mo figure is only a starting point confirmed after provider review
- Domain was registered in April 2026 — a brand-new practice with no independent reviews found
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.